Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To determine whether gastric inhibitory polypeptide (GIP) promotes the clearance of chylomicron triglycerides (TG) from the circulation in dogs, chyle collected from donor dogs via a thoracic duct fistula was infused at a rate of 2 ml/min i.v. into normal recipient dogs during an infusion of either porcine GIP (1 microgram/kg per h) or saline as a control. In the GIP-infused dogs the rise in plasma TG was significantly below that of the control animals [mean peak of 36 +/- 4 mg/dl vs. 82 +/- 18 mg/dl (P less than 0.05)]. It is concluded that GIP exerts an effect upon the removal of chylomicron TG from the blood. The results suggest that GIP may play a physiologic role in the disposition of ingested fat.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
“These data are congruent with GIP’s role in facilitating triglyceride storage in adipose tissue (Eckel et al., 1979; Wasada et al., 1981).”
ResultGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“Biological effects in human studies Insulin secretion (healthy subjects) Stimulation Stimulation [52] (Type 2 diabetes) Weak stimulation Stimulation [52] Glucagon secretion (healthy subjects) Stimulation Suppression [52,95] (Type 2 diabetes) No effect Suppression [79,181] Gastric emptying No effect Deceleration [50,10…”
BackgroundNew developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2010) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 275
GIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266
Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609088200 · Cited by 216
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
New insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194
Asmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184
“Several animal studies support the idea that glucose-dependent insulinotropic polypeptide (GIP) may play a direct role in lipid metabolism, which could be to ensure efficient deposition of dietary fat in body stores in times of plenty (1,2).”
BackgroundGIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
Hansotia, T., & Drucker, D. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 183
“GIP infusion promotes triglyceride clearance from the circulation in dogs [126] and inhibits the lipolytic effect of glucagon on adipocytes [127,128].”
BackgroundReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180
Gut hormones and diabetes mellitus
Creutzfeldt, W., & Nauck, M. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080206 · Cited by 176
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“Consistent with this, GIP promotes clearance of circulating TAGs in dogs (168) and enhances adipose tissue TAG accumulation in rats (169) and humans (170).”
BackgroundVaccination against GIP for the Treatment of Obesity
Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136
“Specifically, GIP has been shown to promote triglyceride clearance from the circulation [13,14], a process partly mediated by its ability to stimulate lipoprotein lipase activity [15].”
BackgroundKim, S.-J., Nian, C., & McIntosh, C. H. S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006841 · Cited by 133
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704896200 · Cited by 118
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Genetic Mutations Affecting Human Lipoproteins, Their Receptors, and Their Enzymes
Zannis, V. I., Kardassis, D., & Zanni, E. E. (1993) · Advances in Human Genetics 21 · doi:10.1007/978-1-4615-3010-7_3 · Cited by 78
McIntosh, C. H. S., Bremsak, I., Lynn, F. C., Gill, R., Hinke, S. A., Gelling, R., Nian, C., McKnight, G., Jaspers, S., & Pederson, R. A. (1999) · Endocrinology · doi:10.1210/endo.140.1.6464 · Cited by 73
“Administration of GIP promoted chylomicron-associated triglyceride clearance from blood in dogs (11), and reduced peak plasma triglyceride levels during an intraduodenal fat infusion in rats (12).”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Genetic Mutations Affecting Human Lipoprotein Metabolism
Zannis, V. I., & Breslow, J. L. (1985) · Advances in Human Genetics 14 · doi:10.1007/978-1-4615-9400-0_3 · Cited by 65
GIP increases insulin receptor affinity and cellular sensitivity in adipocytes
Starich, G. H., Bar, R. S., & Mazzaferri, E. L. (1985) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1985.249.6.e603 · Cited by 56
Nie, Y., Ma, R. C., Chan, J. C. N., Xu, H., & Xu, G. (2012) · The FASEB Journal · doi:10.1096/fj.11-196782 · Cited by 53
Samms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
Dekker, M. J., Graham, T. E., Ooi, T. C., & Robinson, L. E. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.08.004 · Cited by 32
Sachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01940-2 · Cited by 24
Circadian rhythm of gastric inhibitory polypeptide (GIP) in man
Salera, M., Giacomoni, P., Pironi, L., Ustra, C., Capelli, M., Giorgi, A., Miglioli, M., & Barbara, L. (1983) · Metabolism · doi:10.1016/0026-0495(83)90150-6 · Cited by 23
Metadata
- Authors
- Wasada, T., McCorkle, K., Harris, V, Kawai, K., Howard, B., & Unger, R. H.
- Venue
- Journal of Clinical Investigation
- Published
- 1981-10-01
- Volume
- 68
- Issue
- 4
- Pages
- 1106-1107
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2139470767
- Cited by
- 153
- References
- 3
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.